ClinicalTrials.gg
CompletedNCT03003520Updated May 22, 2023Results posted

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of Durvalumab and Rituximab in Lymphoma, Large B-Cell, Diffuse, sponsored by Celgene. Completed at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
106th of 211
46 · median 46
Started
2017
with 1 other
Phase 2
119 of 218
12 open now
Registered
158th of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 106th largest by enrollment of the 211 interventional ones that give a count, is one of 2 that started in 2017, is one of 119 in phase 2, and was the 158th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in previously untreated subjects with high-risk diffuse large B-cell lymphoma (DLBCL). Induction treatment with R-CHOP (± lenalidomide) will last for a total of up to 6 to 8 treatment cycles (21 day cycles), and the total time on study treatment, including durvalumab consolidation, will last up to 12 months.

On 05-Sep-2017, the US FDA has issued a Partial Clinical Hold on this study resulting in the discontinuation of enrollment into Arm B (Durvalumab + Lenalidomide + R-CHOP). After the US FDA Partial Clinical Hold, new eligible participants have been enrolled in Arm A (Durvalumab + R-CHOP).

Read the detailed description

This research study is conducted in participants with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). Patients with high-risk DLBCL typically have insufficient therapeutic outcomes. Therefore, the addition of novel agents to the currently used induction therapy (R-CHOP) is a rational approach to improve therapeutic outcomes in this disease setting.

Based on pre-clinical and clinical observations, it is hypothesized that durvalumab will have activity in DLBCL because the PD 1/PD L1 pathway is involved in the pathophysiology of DLBCL. In particular, the addition of durvalumab may augment the anti-tumor activity of R-CHOP against high-risk DLBCL sub-types.

The safety of durvalumab has already been explored. However, as there is limited clinical experience with durvalumab in DLBCL, the study is divided into two stages:

  • A Safety Run-in Stage to evaluate the safety of the treatment combinations until at least 10 subjects are included in each of the two treatment arms
  • An Expansion Stage to analyze the clinical activity of the treatment combinations

Results posted following Primary Outcome Completion date are based on a database cut-off of August 2, 2018.

03

Conditions studied

  • Lymphoma, Large B-Cell, Diffuse

Keywords

  • Lymphoma
  • Diffuse-large B-Cell Lymphoma
  • Durvalumab
  • Anti-PD-L1 Antibody
  • MEDI4736
  • Immune Checkpoint
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone/Prednisolone
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CD20+Diffuse Large B-Cell Lymphoma.
  2. Ann Arbor stage 3 or 4 or stage 2 with bulky disease
  3. High or high-intermediate disease risk.
  4. No prior anti-lymphoma treatment.
  5. Subject is willing and able to undergo .
  6. Investigator considers R-CHOP immunochemotherapy appropriate.
  7. (ECOG) performance status of 0-2.
  8. Adequate hematology laboratory results ( ≥ 1.5 * 10\^9/L, count ≥ 75 * 10\^9/L, ≥ 10.0 g/dL).
  9. Adequate biochemistry laboratory results ( (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 * ; ≤ 2.0 mg/dL; of ≥ 40 mL/min).
  10. Bi-dimensionally (> 2.0 cm).
  11. Subject is using effective .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of lymphoma other than Diffuse Large B-Cell Lymphoma.
  2. Composite lymphoma or transformed lymphoma.
  3. Primary or secondary Central Nervous System involvement by lymphoma.
  4. Seropositive or active viral infection with virus, or virus.
  5. History of other , unless disease-free for ≥ 5 years.
  6. \< 50%.
  7. Peripheral neuropathy ≥ Grade 2.
  8. Prior use of lenalidomide, or monoclonal antibodies against , PD-1, or PD-L1.
  9. High risk of developing thromboembolic events, who are unwilling to take venous thromboembolism prophylaxis.
  10. Active or prior documented or inflammatory disorders within the past 3 years.
  11. Current or prior use of medication within 28 days before start of treatment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    DUR + R-CHOP

    On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m\^2, doxorubicin 50 mg/m\^2, vincristine 1.4 mg/m\^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m\^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles. Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.

    Drug: Durvalumab · Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: Prednisone

  • Experimental
    DUR + R2-CHOP

    Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles. Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months. Enrollment into Arm B was discontinued.

    Drug: Durvalumab · Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Cyclophosphamide · Drug: Prednisone · Drug: Lenalidomide

Interventions

  • Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection. Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion.

    Also known as: MEDI4736, IMFINZI™, DUR

  • Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.

    Also known as: RITUXAN®

  • A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.

    Also known as: Adriamycin

  • A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.

    Also known as: leurocristine, Oncovin

  • A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.

    Also known as: cytophosphane, Cytoxan

  • Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle. Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm.

    Also known as: corticosteroid, prednisolone

  • Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.

    Also known as: Revlimid®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy

    The primary efficacy analysis evaluated the complete response rate (CRR) at the end of the induction therapy in the efficacy evaluable population in a comparative manner against historical control. The response to treatment was assessed according to the 2014 International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) (Cheson, 2014). CR was defined as a complete metabolic response and radiographic evidence showing target nodes/nodal masses regressed to ≤ 1.5 cm in longest diameter, no new lesions, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. Clopper-Pearson two-sided 95% confidence interval is reported. Null hypothesis for the primary endpoint was rejected if the lower limit of the confidence interval for the complete response rate at the completion of the induction therapy in the efficacy evaluable population is above 55%.

    Time frame: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

Secondary outcomes

  1. Percentage of Participants Who Responded During Induction and Continued Into Consolidation Therapy (Database Cutoff Date: 02-Aug-2018)

    The percentage of participants who achieved a partial response (PR) or complete response (CR) at the end of Induction and continued into consolidation period in the efficacy evaluable population in a comparative manner against historical control. The response to treatment was assessed according to the 2014 International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) (Cheson, 2014). CR was defined in outcome #1. PR was defined as a partial metabolic response and radiographic evidence showing ≥ 50% decrease in sum of perpendicular diameters (SPD) of up to 6 target measurable nodes and extranodal sites, no new lesions, spleen must have regressed \> 50% in length beyond normal, and residual bone marrow involvement improved from baseline. Clopper-Pearson two-sided 95% confidence interval is reported. Null hypothesis was rejected if the lower limit of the confidence interval for the rate of subjects who continue consolidation therapy out of all subjects.

    Time frame: From first dose of study drug to completion of at least one cycle in the Consolidation Period (Day 1 up to Week 52)

  2. Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) CD8 T-Cell Density

    Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

    Time frame: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

  3. Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Total Percentage

    Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

    Time frame: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

  4. Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Percentage of Tumor Cells

    Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

    Time frame: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

  5. Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for the Interferon Gamma Score (IFNG-Score) From Ribonucleic Acid (RNA)-Sequencing Data

    Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

    Time frame: Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).

  6. Participants With Treatment Emergent Adverse Events (TEAE)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03): - Grade 1 = Mild (no limitation in activity or intervention); - Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); - Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); - Grade 4 = Life-threatening; - Grade 5 = Death. Relation to IP is determined by the investigator.

    Time frame: From the date of the first dose of study drug to within 90 days after the last dose of durvalumab or 28 days after the last dose of any investigational product (IP) whichever is greater. (Up to approximately 72 weeks)

07

Results

Posted Sep 16, 2019
Limitations and caveats
After the US FDA Partial Clinical Hold, enrollment of new participants into Arm B was discontinued. If receiving clinical benefit at the discretion of the Investigator, participants could continue treatment in Arm B after being reconsented. Any newly enrolled participant with DLBCL of ABC COO subtype after the US FDA Partial Clinical Hold could continue induction therapy on Arm A after Cycle 1.

Participant flow

Participant flow — Overall Study
MilestoneDUR + R-CHOPDUR + R2-CHOP
Started433
Completed induction treatment313
Completed consolidation treatment142
Completed142
Not completed291
Withdrew: Adverse event90
Withdrew: Death10
Withdrew: Other reasons40
Withdrew: Withdrawal by subject60
Withdrew: Progressive disease91

Outcome measures

PrimaryPercentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy

The primary efficacy analysis evaluated the complete response rate (CRR) at the end of the induction therapy in the efficacy evaluable population in a comparative manner against historical control. The response to treatment was assessed according to the 2014 International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) (Cheson, 2014). CR was defined as a complete metabolic response and radiographic evidence showing target nodes/nodal masses regressed to ≤ 1.5 cm in longest diameter, no new lesions, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. Clopper-Pearson two-sided 95% confidence interval is reported. Null hypothesis for the primary endpoint was rejected if the lower limit of the confidence interval for the complete response rate at the completion of the induction therapy in the efficacy evaluable population is above 55%.

Time frame:
From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy
percentage of participantsDUR + R-CHOPDUR + R2-CHOP
Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy54.1 (36.9 to 70.5)66.7 (9.4 to 99.2)
SecondaryPercentage of Participants Who Responded During Induction and Continued Into Consolidation Therapy (Database Cutoff Date: 02-Aug-2018)

The percentage of participants who achieved a partial response (PR) or complete response (CR) at the end of Induction and continued into consolidation period in the efficacy evaluable population in a comparative manner against historical control. The response to treatment was assessed according to the 2014 International Working Group (IWG) Response Criteria for Non-Hodgkin's Lymphoma (NHL) (Cheson, 2014). CR was defined in outcome #1. PR was defined as a partial metabolic response and radiographic evidence showing ≥ 50% decrease in sum of perpendicular diameters (SPD) of up to 6 target measurable nodes and extranodal sites, no new lesions, spleen must have regressed \> 50% in length beyond normal, and residual bone marrow involvement improved from baseline. Clopper-Pearson two-sided 95% confidence interval is reported. Null hypothesis was rejected if the lower limit of the confidence interval for the rate of subjects who continue consolidation therapy out of all subjects.

Time frame:
From first dose of study drug to completion of at least one cycle in the Consolidation Period (Day 1 up to Week 52)
Reported as:
Number · percentage of participants
Percentage of Participants Who Responded During Induction and Continued Into Consolidation Therapy (Database Cutoff Date: 02-Aug-2018)
percentage of participantsDUR + R-CHOPDUR + R2-CHOP
Percentage of Participants Who Responded During Induction and Continued Into Consolidation Therapy (Database Cutoff Date: 02-Aug-2018)67.6 (50.2 to 82.0)66.7 (9.4 to 99.2)
SecondaryPercentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) CD8 T-Cell Density

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

Time frame:
Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) CD8 T-Cell Density
percentage of participantsHigh Group for CD8 DensityLow Group for CD8 Density
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) CD8 T-Cell Density6764
Statistical analysis
  • High Group for CD8 Density vs Low Group for CD8 Density · Fisher Exact · p = >0.99 (Significance defined as 0.05.)
  • High Group for CD8 Density vs Low Group for CD8 Density · Wilcoxon (Mann-Whitney) · p = 0.872 (Significance defined as 0.05.) · Auc-roc: 0.477
SecondaryPercentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Total Percentage

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

Time frame:
Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Total Percentage
percentage of participantsHigh Group for PDL1 % of Total CellsLow Group for PDL1 % of Total Cells
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Total Percentage7520
Statistical analysis
  • High Group for PDL1 % of Total Cells vs Low Group for PDL1 % of Total Cells · Fisher Exact · p = 0.0403 (Significance defined as 0.05.)
  • High Group for PDL1 % of Total Cells vs Low Group for PDL1 % of Total Cells · Wilcoxon (Mann-Whitney) · p = 0.523 (Significance defined as 0.05.) · Auc-roc: 0.583
SecondaryPercentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Percentage of Tumor Cells

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

Time frame:
Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Percentage of Tumor Cells
percentage of participantsHigh Group for PDL1 % of Tumor CellsLow Group for PDL1 % of Tumor Cells
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for Immunohistochemistry (IHC) Programmed Death Ligand - 1 (PDL1) Percentage of Tumor Cells6456
Statistical analysis
  • High Group for PDL1 % of Tumor Cells vs Low Group for PDL1 % of Tumor Cells · Fisher Exact · p = >0.99 (Significance defined as 0.05.)
  • High Group for PDL1 % of Tumor Cells vs Low Group for PDL1 % of Tumor Cells · Wilcoxon (Mann-Whitney) · p = 0.557 (Significance defined as 0.05.) · Auc-roc: 0.583
SecondaryPercentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for the Interferon Gamma Score (IFNG-Score) From Ribonucleic Acid (RNA)-Sequencing Data

Data in the analysis include all participants who received durvalumab, irrespective of the study arm in which they enrolled, because the selected biomarkers have been associated with response in other anti-PD1 or anti-PDL1 studies, such as durvalumab. IHC analysis was performed on the baseline tumor biopsy to quantify CD8 T-cell density. Participants with 'high' values, i.e. above the threshold defined as the median value of 774 cells/mm\^2 found in commercial DLBCL samples using matched analytical methods, were predicted to be responders to treatment with durvalumab. The definition of a complete response was that used in the primary outcome.

Time frame:
Biomarker biopsies: Days -28 to Day -1. Clinical response: From first dose of study drug to end of Induction therapy (Day 1 up to Week 26 - maximum duration of Induction Period).
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for the Interferon Gamma Score (IFNG-Score) From Ribonucleic Acid (RNA)-Sequencing Data
percentage of participantsHigh Group for RNA IFN Gamma ScoreLow Group for RNA IFN Gamma Score
Percentage of Participants Who Achieved a Clinical Response in the Biomarker Subpopulation for the Interferon Gamma Score (IFNG-Score) From Ribonucleic Acid (RNA)-Sequencing Data4360
Statistical analysis
  • High Group for RNA IFN Gamma Score vs Low Group for RNA IFN Gamma Score · Fisher Exact · p = 0.662 (Significance defined as 0.05.)
  • High Group for RNA IFN Gamma Score vs Low Group for RNA IFN Gamma Score · Wilcoxon (Mann-Whitney) · p = 0.399 (Significance defined as 0.05.) · Auc-roc: 0.6
SecondaryParticipants With Treatment Emergent Adverse Events (TEAE)

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03): - Grade 1 = Mild (no limitation in activity or intervention); - Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); - Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); - Grade 4 = Life-threatening; - Grade 5 = Death. Relation to IP is determined by the investigator.

Time frame:
From the date of the first dose of study drug to within 90 days after the last dose of durvalumab or 28 days after the last dose of any investigational product (IP) whichever is greater. (Up to approximately 72 weeks)
Reported as:
Count of participants · Participants
Participants With Treatment Emergent Adverse Events (TEAE)
ParticipantsDUR + R-CHOPDUR + R2-CHOP
>= 1 Treatment-emergent adverse event (TEAE)433
>=1 TEAE related to durvalumab333
>=1 TEAE related to R-CHOP403
>=1 TEAE related to lenalidomide—3
>=1 TEAE related to durvalumab or any other IP413
>=1 TEAE severity grade 3-4373
>=1 TEAE severity grade 3-4 related to durvalumab181
>=1 TEAE severity grade 3-4 related to R-CHOP273
>=1 TEAE severity grade 3-4 related to lenalidomid—2
>=1 TEAE severity grade 3-4 related to any IP313
>=1 TEAE severity grade 530
>=1 TEAE severity grade 5 related to any IP00
>=1 serious TEAE231
>=1 serious TEAE related to durvalumab101
>=1 serious TEAE related to R-CHOP101
>=1 serious TEAE related to lenalidomide—1
>=1 serious TEAE related to any IP141
>=1 leading to discontinuation of durvalumab130
>=1 leading to discontinuation of R-CHOP40
>=1 leading to discontinuation of lenalidomide—0
>=1 leading to discontinuation of any IP130
>=1 leading to interruption of durvalumab152
>=1 leading to interruption of R-CHOP121
>=1 leading to interruption of lenalidomide—2
>=1 leading to interruption of any IP183
>=1 leading to infusion interruption of durvalumab20
>=1 leading to dose reduction of vincristine41
>=1 leading to dose reduction of lenalidomide—1

Adverse events

Collected over AEs and SAEs were assessed from first dose to 90 days after the last dose of durvalumab or 28 days after the last dose of any other IP, whichever is later (up to approximately 72 weeks) and up to 5 years after enrollment (C1D1) of the last participant to receive lenalidomide (up to approximately 5 years). All-Cause Mortality was assessed in participants from their first dose to their study completion (up to approximately 5 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DUR + R-CHOP5/43 (11.6%)23/43 (53.5%)43/43 (100%)
DUR + R2-CHOP1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventDUR + R-CHOPDUR + R2-CHOP
Febrile neutropeniaBlood and lymphatic system disorders6/431/3
PyrexiaGeneral disorders3/430/3
Atrial fibrillationCardiac disorders2/430/3
NauseaGastrointestinal disorders2/430/3
General physical health deteriorationGeneral disorders2/430/3
InfectionInfections and infestations2/430/3
InfluenzaInfections and infestations2/430/3
PneumoniaInfections and infestations2/430/3
AnaemiaBlood and lymphatic system disorders1/430/3
LeukopeniaBlood and lymphatic system disorders1/430/3
Most frequent other events
Showing 10 of 66
Most frequent other events
EventDUR + R-CHOPDUR + R2-CHOP
NeutropeniaBlood and lymphatic system disorders21/433/3
ConstipationGastrointestinal disorders9/432/3
NauseaGastrointestinal disorders18/432/3
StomatitisGastrointestinal disorders8/432/3
FatigueGeneral disorders26/432/3
Peripheral sensory neuropathyNervous system disorders23/432/3
AnaemiaBlood and lymphatic system disorders7/431/3
LeukopeniaBlood and lymphatic system disorders7/431/3
ThrombocytopeniaBlood and lymphatic system disorders4/431/3
HypoacusisEar and labyrinth disorders0/431/3

Baseline characteristics

Safety population

Age, Continuous
Age, Continuous(years)DUR + R-CHOPDUR + R2-CHOPTotal
Mean61.1 ± 12.7767.7 ± 8.6261.5 ± 12.57
Age, Customized
Age, Customized(Participants)DUR + R-CHOPDUR + R2-CHOPTotal
<65 years23124
>=65 years20222
Sex: Female, Male
Sex: Female, Male(Participants)DUR + R-CHOPDUR + R2-CHOPTotal
Female17118
Male26228
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DUR + R-CHOPDUR + R2-CHOPTotal
Hispanic or Latino000
Not Hispanic or Latino43346
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DUR + R-CHOPDUR + R2-CHOPTotal
American Indian or Alaska Native000
Asian000
Black or African American000
Native Hawaiian or Other Pacific Islander000
White42345
Not Colected or Reported000
Other101
Eastern Cooperative Oncology Group (ECOG)
Eastern Cooperative Oncology Group (ECOG)(Participants)DUR + R-CHOPDUR + R2-CHOPTotal
0 = Fully Active16218
1 = Restricted activity but ambulatory19019
2 = Ambulatory but unable to work819
3 = Limited Self-Care000
4 = Completely Disabled, No self-care000
Ann Arbor Stage at Diagnosis
Ann Arbor Stage at Diagnosis(Participants)DUR + R-CHOPDUR + R2-CHOPTotal
Stage I000
Stage II000
Stage III9211
Stage IV34135
Presence of Bulky Disease at Baseline
Presence of Bulky Disease at Baseline(Participants)DUR + R-CHOPDUR + R2-CHOPTotal
Yes21223
No22123

1 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Mid Ohio Oncology Hematology Inc
    Columbus, Ohio 43219, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Innsbruck Medical University Department of Internal Medicine
    Innsbruck, 6020, Austria
  • Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Local Institution - 101
    Vienna, 1190, Austria
  • Medical University of Vienna Internalmedicine 1, Hematology
    Vienna, 1190, Austria
  • Hanusch Krankenhaus
    Wien, 1140, Austria
  • Aarhus Sygehus
    Arhus C, DK-8000, Denmark
  • Rigshospitalet, Kobenhavns Universitet - Centre for Clinical Intervention Research - The Copenhagen
    Copenhagen, 2100, Denmark
  • Odense Universitetshospital
    Odense C, DK5000, Denmark
  • (North Estonia Medical Centre) - Onkoloogia-ja Hematoloogiakliinik
    Tallinn, 13419, Estonia
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • University Hospital Birmingham
    Birmingham, B15 2TH, United Kingdom
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine
    Oxford, 0X3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Apr 2022, 61 months.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 61 months is above that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2016
First posted
Dec 28, 2016
StartActual
Feb 28, 2017
Primary completionActual
Apr 24, 2022
CompletionActual
Apr 24, 2022
Results first posted
Sep 16, 2019
Last update
May 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03003520
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 28, 2016
Start date
Feb 28, 2017
Primary completion
Apr 24, 2022
Completion
Apr 24, 2022
Results posted
Sep 16, 2019
Last update
May 22, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Rituximab · Doxorubicin · Vincristine · Cyclophosphamide · Prednisone

Start the discussion